RxDoctor Payments Data

Mergie Desir

Family Medicine · Fresh Meadows, NYNPI 1053360743

Payments from drug & device makers

$1,181in general payments, 2019–2025

Across 57 payments — averaging $20.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$440
  • Astellas Pharma US Inc$163
  • AstraZeneca$115
  • Novo Nordisk$88
  • GSK$72
  • Amarin Pharma, Inc.$61
  • plus $243 from 9 others

What the payments were for

  • Food & beverage$1,10493%
  • Education$777%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,181 in reported general payments places this provider in the 65th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$10,849
Medicare patients
24
Services billed
117

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide61$89,157
JardianceEmpagliflozin37$47,415
EliquisApixaban42$46,725
JanuviaSitagliptin Phosphate33$44,458
TrulicityDulaglutide22$34,119
MounjaroTirzepatide12$16,090
JanumetSitagliptin Phos/Metformin Hcl14$13,641
LinzessLinaclotide13$7,706
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$5,836
Novolog FlexpenInsulin Aspart29$4,365
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate17$3,953
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$3,587
Albuterol Sulfate HfaAlbuterol Sulfate103$2,966
Atorvastatin Calcium281$2,518
ShingrixVaricella-Zoster Ge/As01b/Pf12$2,190

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$88$89,15761 claims
MerckJanuvia, Janumet$42$58,10047 claims
Lilly USA, LLCTrulicity, Mounjaro$440$50,20934 claims
PfizerEliquis$46$46,72542 claims
AbbVieLinzess$16$7,70613 claims
GSKShingrix$72$2,19012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,321 family medicine providers in New York.

Other family medicine in Fresh Meadows

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →